Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis

Published on 01 Jun 2023
Last Updated on 01 Jun 2023

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Secukinumab 150 mg/mL solution for injection in prefilled pen for treating adults with active non-radiographic axial spondyloarthritis

Funding status

Secukinumab 150 mg/mL solution for injection in prefilled pen is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2023.

Secukinumab should be used in line with additional clinical criteria for initial and continuing prescriptions for adult patients with active non-radiographic axial spondyloarthritis.

MAF assistance does not apply to ixekizumab, or any other formulations or strengths of secukinumab.

Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis (Published 1 June 2023) [PDF, 123 KB]

PES Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis (Published 1 June 2023) [PDF, 70 KB]